NCT07105722View on ClinicalTrials.gov

A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

June 18, 2026

Study Completion Date

June 18, 2026

Conditions
Pneumonia, Bacterial
Interventions
BIOLOGICAL

Pn-MAPS30plus

The Pn-MAPS30plus vaccine will be administered intramuscularly.

COMBINATION_PRODUCT

PCV20

The PCV20 vaccine will be administered intramuscularly.

Trial Locations (4)

3002

RECRUITING

GSK Investigational Site, East Melbourne

3124

RECRUITING

GSK Investigational Site, Camberwell

3153

RECRUITING

GSK Investigational Site, Bayswater

5067

RECRUITING

GSK Investigational Site, Norwood

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT07105722 - A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age | Biotech Hunter | Biotech Hunter